Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11586MR)

This product GTTS-WQ11586MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11586MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15794MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ187MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ15338MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ15863MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ6642MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ15714MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ13983MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ10517MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY3002813
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW